av Helene Dugstad | apr 15, 2024
Background Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. CAR-T cell therapy has been tested against various targets in ovarian cancer and one of the candidates is the MUC16 ectodomain. This ectodomain remains on...
av Aina Rengmark | apr 8, 2024
Business opportunity Therapy employing T cells modified with chimeric antigen receptors (CARs) is effective in hematological malignancies but not yet in solid tumors. CAR T cell activity in solid tumors is limited by immunosuppressive factors, including transforming...
av Helene Dugstad | mar 21, 2024
Background Dogs spontaneously develop cancer just like humans. Canine osteosarcoma is an aggressive bone tumour with high rate of metastasis (appr. 90%). Current treatment is amputation and adjuvant chemotherapy, however, many dogs are euthanized. The field of cancer...
av Helene Dugstad | feb 28, 2024
Background Colorectal cancer (CRC) is the third most common cancer worldwide. Despite fair survival for localized CRC, metastatic CRC has a five-year survival rate of only ~11%. Neoantigens are excellent targets for adoptive cellular immunotherapy since they are...
av Helene Dugstad | sep 20, 2022
Poor persistence of the T-cell product represents an important challenge with CAR-T cell therapy. This is often due to constitutive activity of the CAR leading to T cells exhaustion before a therapeutic effect can be achieved. To address this challenge, an original...
